论文部分内容阅读
本文报告我科1985年5月至1987年5月用EBVD方案治疗何杰金氏病20例和CEOP方案治疗非何杰金氏淋巴瘤27例的近期疗效和毒性反应。全组病例均经病理证实。何杰金氏病18例可评价疗效,CR8例(CR率44.4％),PR7例,(PR率38.9％)总有效率83.3％;非何杰金氏淋巴病23例可评价疗效,CR16例(CR率69.6％),PR7例(PR率30.4％),总有效率100％。 毒性反应,消化道反应多数较轻,不需治疗,白细胞下降不显著,4例因白细胞低合并感染,无死亡者;多数有脱发;未见肝肾功能异常;心电图异常者12次;未见心脏扩大或心衰者。 本文结果表明表阿霉素疗效与阿霉素相似,毒副作用较阿霉素轻。
This article reports our department from May 1985 to May 1987 EBVD regimen in the treatment of 20 cases of Hodgkin’s disease and CEOP regimen in the treatment of non-Hodgkin’s lymphoma in 27 cases of short-term efficacy and toxicity. All patients were confirmed by pathology. Hodgkin’s disease 18 cases can be evaluated curative effect, CR8 cases (CR rate 44.4%), PR7 cases, (PR rate 38.9%) total effective rate 83.3%; non-Hodgkin’s lymphoma 23 cases can evaluate the curative effect CR16 (CR rate 69.6%), PR7 cases (PR rate 30.4%), the total efficiency of 100%. Toxic reactions, most of the gastrointestinal tract reactions lighter, without treatment, leukopenia was not significant, 4 cases of low white blood cells due to infection, no death; most have hair loss; no liver and kidney dysfunction; ECG abnormalities were 12 times; Heart enlargement or heart failure. The results of this paper show that the efficacy of epirubicin and doxorubicin similar side effects than doxorubicin light.